Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02957461 · ClinicalTrials.gov registry record
Validation of Brain Function Assessment Algorithm for mTBI/Concussion in College Athletes
A clinical trial, sponsored by BrainScope Company.
- Completed
- Registry status
- 420
- Enrollment target
NCT02957461: Completed study, sponsored by BrainScope Company.
NCT02957461 is a clinical trial that has completed, run by BrainScope Company. The registered enrollment target is 420 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02957461 has completed, sponsored by BrainScope Company.
- COMPLETED
- Registry status
- 420 participants
- Enrollment target
Study Summary
This study is Part 1 of data collection from 18-25 years old subject population for validation of previously derived algorithms. This data will be combined with that collected under NCT03671083 (Part 2 with subject age range 13-25 years) for the final analyses of validation of the algorithms.
Primary Outcome
Sensitivity and specificity forthe identification of the likelihood of concussion/mTBI at the time of injury using a multi-modal EEG-based Concussion Index (CI)
Interventions
- DEVICE BrainScope Ahead 200iD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2017-02-03 |
| Est. Completion | 2018-03-02 |
What the finished NCT02957461 record still lists
NCT02957461 is an observational study that tracks outcomes without assigning an intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which BrainScope Ahead 200iD is the first listed.
NCT02957461 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02957461 about?
NCT02957461 is a clinical study titled "Validation of Brain Function Assessment Algorithm for mTBI/Concussion in College Athletes". This study is Part 1 of data collection from 18-25 years old subject population for validation of previously derived algorithms. This data will be combined with that collected under NCT03671083 (Part 2 with subject age range 13-25 years) for the final analyses of validation of the algorithms.
What is the current status of trial NCT02957461?
This trial is currently completed. The enrollment target is 420 participants. The study started on 2017-02-03. Estimated completion is 2018-03-02.
What interventions are being tested in trial NCT02957461?
The interventions under investigation include: BrainScope Ahead 200iD (DEVICE).
Who is sponsoring clinical trial NCT02957461?
This trial is sponsored by BrainScope Company, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI